The Pharmalot View By Ed Silverman The art of the deal? Why a money-back guarantee for drugs is a bad idea
The Pharmalot View By Ed Silverman If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon
The Pharmalot View By Ed Silverman It’s time to make it legal for Americans to order prescription drugs from abroad
The Pharmalot View By Ed Silverman US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it
The Pharmalot View By Ed Silverman The Trump administration could bring down drug prices. But it would take guts
The Pharmalot View By Ed Silverman Dear Vice President Pence: Stop peddling false hopes to dying patients
The Pharmalot View By Ed Silverman Pharma trade group vows to review membership criteria, but is this an empty promise?
The Pharmalot View By Ed Silverman Trump is considering a radical to lead FDA. That’s dangerous for public health
The Pharmalot View By Ed Silverman Trump should be good medicine for the pharmaceutical industry. Here’s why
The Pharmalot View By Ed Silverman Pharma may have defeated Prop 61, but state battles over pricing will continue
The Pharmalot View By Ed Silverman Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?
The Pharmalot View By Ed Silverman Health officials should reject latest gambit by EpiPen maker to feed at the public trough
The Pharmalot View By Ed Silverman Behind the grandstanding, Congress may have taken a key step to clarifying drug prices
The Pharmalot View By Ed Silverman Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?
The Pharmalot View By Ed Silverman The secretive system for vetting cancer drug use needs an urgent overhaul
The Pharmalot View By Ed Silverman Pharma should not be allowed a loophole for reporting financial ties to docs
The Pharmalot View By Ed Silverman The ‘gouge factor’: Big companies want transparency in drug price negotiations
The Pharmalot View By Ed Silverman Pharma trade group says price gougers are outliers, but then accepts two more
The Pharmalot View By Ed Silverman Pfizer wins big in opioid deal with Chicago. But what does the city get?
